Xin Sun, Yan An, Xiandong Zeng, Yanhua Jiang
Journal: Frontiers in endocrinology 2026;17():1754896
PMID: 41847451
BACKGROUND
Diabetic retinopathy (DR) is a common chronic complication of diabetes mellitus. Endothelin-1 (ET-1) has been identified as a key regulator of various ocular functions, including vascular perfusion, aqueous humor dynamics, and retinal ganglion cell survival. Substantial evidence further underscores the critical involvement of ET-1 in the pathogenesis and progression of DR. Elevated ET-1 levels have been reported in patients with DR; however, findings across studies are inconsistent.
AIM
This meta-analysis aimed to statistically evaluate the level of ET-1 in patients with DR.
METHODS
A systematic literature search was conducted across five electronic databases (PubMed, Web of Science, OVID, Elsevier Science Direct, and Wiley Online Library). The search strategy targeted the terms "Endothelin-1" or "ET-1" in conjunction with "Diabetic retinopathy" or "DR" in title and abstract fields. Results are presented as standardized mean differences (SMD) with 95% confidence intervals (CI).
RESULTS
Ten articles (346 cases and 425 controls) were included in the meta-analysis. The results of the meta-analysis indicated that the circulating ET-1 in patients with DR was significantly higher than that of the controls (SMD: 1.73, 95% CI: 0.90, 2.56). Furthermore, circulating ET-1 in patients with DR was also significantly higher than those in healthy individuals or diabetic patients without retinopathy, respectively.
CONCLUSIONS
This meta-analysis is the first to systematically assess ET-1 levels in patients with DR. The findings of this study indicate the potential application of ET-1 as a biomarker for monitoring DR progression.
SYSTEMATIC REVIEW REGISTRATION
https://www.crd.york.ac.uk/prospero/, identifier CRD420251156225.
Copyright © 2026 Sun, An, Zeng and Jiang.
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.